SGEN up +3.44% percent right now. $SGEN High is at 36.17 and the Low 34.14 with current volume of 1,663,400.
Recent News posted below.
SGEN Seattle Genetics Recent Headline News
3 Biotech Stocks to Watch in November
Motley Fool Staff - Motley Fool - Sat Nov 08, 10:03AM CST
Investing in biotech companies can be tricky, especially for investors who don't have a scientific background or who don't completely understand the process of bringing new drugs to the marketplace. Fortunately, the Fool is here to help. We asked...
AVNR: 13.02 (-0.19), SGEN: 36.05 (+1.20), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21), GSK: 44.91 (+0.16)
Seattle Genetics to Present Clinical Data from Broad ADCETRIS(R) (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014
Business Wire - Fri Nov 07, 8:00AM CST
--Fifteen ADCETRIS Data Presentations, Including Seven Oral Presentations, Support Goal to Establish ADCETRIS as the Foundation of Therapy for CD30-Positive Malignancies
SGEN: 36.05 (+1.20)
Seattle Genetics (SGEN) Shows Signs Of Being Water-Logged And Getting Wetter
at The Street - Thu Nov 06, 9:18AM CST
Trade-Ideas LLC identified Seattle Genetics (SGEN) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
SGEN: 36.05 (+1.20)
Research and Markets: Mycosis Fungoides Therapeutics Pipeline Review, H2 2014 Report Featuring Sanofi, Seattle Genetics, Inc, Echo Therapeutics, Inc. & Actelion Ltd
Business Wire - Thu Nov 06, 4:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mlg9h9/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2014" report to their offering.
ECTE: 0.67 (unch), SGEN: 36.05 (+1.20)
Mycosis Fungoides Therapeutics Pipeline Review, H2 2014 Report Featuring Sanofi, Seattle Genetics, Inc, Echo Therapeutics, Inc. & Actelion Ltd
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/n96mgn/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mycosis Fungoides, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mycosis Fungoides and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - Seattle Genetics, Inc. - Echo Therapeutics, Inc. - Actelion Ltd Drug Profiles - brentuximab vedotin - mechlorethamine hydrochloride - alemtuzumab - methotrexate - NSC-678515 - CIGB-128 For more information visit http://www.researchandmarkets.com/research/n9..._fungoides
ECTE: 0.67 (unch), SGEN: 36.05 (+1.20)
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014 - 38 Companies & 67 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/rdllgl/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Idera Pharmaceuticals, Inc. - Mesoblast Limited - Jazz Pharmaceuticals plc - Alexion Pharmaceuticals, Inc. - Soligenix, Inc. - NeoStem, Inc. - Pharmacyclics, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Kamada Ltd. - R-Tech Ueno, Ltd. - Omni Bio Pharmaceutical Inc. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/rd...ersus_host
BIIB: 320.75 (-2.72), PCYC: 133.49 (-3.63), PSTI: 2.66 (-0.08), NBS: 4.85 (unch), ALDR: 16.57 (-0.25), IDRA: 2.43 (-0.06), SGEN: 36.05 (+1.20), JAZZ: 170.80 (-1.57), ALXN: 193.81 (+0.67), KMDA: 4.15 (+0.15), ATHX: 1.53 (-0.04), NVS: 91.76 (-0.27)
Seattle Genetics to Present at Credit Suisse Healthcare Conference
Business Wire - Tue Nov 04, 8:00AM CST
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 11, 2014, at 8:30 a.m. Mountain Time. The presentation will be webcast live and available for replay from Seattle Genetics' website at www.seattlegenetics.com in the Investors and News section.
SGEN: 36.05 (+1.20)
Seattle Genetics Gains on Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 11:50AM CST
Seattle Genetics, Inc. (SGEN) reported a loss of 13 cents per share in the third quarter, narrower than the Zacks Consensus Estimate of a loss of 25 cents.
MDVN: 112.77 (+7.82), BIIB: 320.75 (-2.72), SGEN: 36.05 (+1.20), GILD: 106.45 (-0.49)
Cramer Sees HP Entering Sector as Trouble for 3-D Printing Stocks
at The Street - Mon Nov 03, 10:57AM CST
Even though HP won't start shipping its 3-D printing machines in bulk until 2016, it could be a problem for other 3-D printing companies.
BMRN: 83.91 (-0.12), ISIS: 44.59 (-0.66), SGEN: 36.05 (+1.20), GILD: 106.45 (-0.49), SSYS: 103.07 (-3.26), HP: 86.70 (+0.98), REGN: 377.84 (+0.90), CELG: 106.45 (-0.69)
Seattle Genetics, Inc. Posts Record Adcetris Sales
Brian Orelli, The Motley Fool - Motley Fool - Thu Oct 30, 7:27PM CDT
Seattle Genetics is up in after-hours trading after posting record sales for its blood cancer drug Adcetris, and raising guidance for the year. The biotech sold $48 million worth of Adcetris in the U.S. and Canada, a 32% year-over-year increase. ...
SGEN: 36.05 (+1.20), GSK: 44.91 (+0.16)
Seattle Genetics beats Street 3Q forecasts
Automated Insights - Thu Oct 30, 6:13PM CDT
BOTHELL, Wash. (AP) _ Seattle Genetics Inc. (SGEN) on Thursday reported a third-quarter loss of $15.6 million.
SGEN: 36.05 (+1.20)
Seattle Genetics Reports Third Quarter 2014 Financial Results
Business Wire - Thu Oct 30, 3:06PM CDT
---ADCETRIS 2014 Net Sales Guidance Increased to a Range of $172 Million to $177 Million-
SGEN: 36.05 (+1.20)
Aegerion, Seattle Genetics CEOs Accused in Suit of Cocaine Use
at The Street - Mon Oct 27, 9:24AM CDT
Both CEOs deny allegations in an ugly divorce case that they snorted cocaine with a Jefferies & Co. health care investment banker.
SGEN: 36.05 (+1.20), AMGN: 160.25 (-0.10), AEGR: 21.58 (-0.40), REGN: 377.84 (+0.90)
Global B-Cell Non-Hodgkin Lymphoma Therapeutics Pipeline Review H2 2014 - 43 Drug Profiles from 28 Leading Pharma Companies
M2 - Thu Oct 23, 10:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72dlvw/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - Sanofi - Seattle Genetics, Inc. - Genentech, Inc. - MedImmune, LLC - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Biocon Limited - Ono Pharmaceutical Co., Ltd. - Sandoz Inc. - Celgene Corporation - Incyte Corporation - Merck KGaA - Immunomedics, Inc. - Portola Pharmaceuticals, Inc. - Pharmacyclics, Inc. - Takara Bio Inc. - Simcere Pharmaceutical Group - Spectrum Pharmaceuticals, Inc. - Cornerstone Pharmaceuticals, Inc. - LFB S.A. - Eagle Pharmaceuticals Inc. - Areta International s.r.l. - Molecular Templates Inc. - Aprogen, Inc. - BioMedics Japan Inc. For more information visit http://www.researchandmarkets.com/research/72dlvw/bcell
IMMU: 3.61 (+0.05), PTLA: 27.39 (-0.33), PCYC: 133.49 (-3.63), INCY: 69.32 (+0.92), AMGN: 160.25 (-0.10), SPPI: 7.33 (-0.15), BMY: 58.32 (-0.14), EGRX: 12.48 (-0.17), SGEN: 36.05 (+1.20), MRK: 59.34 (+0.08), CELGZ: 3.24 (-0.04)
Seattle Genetics Has Returned 11.5% Since SmarTrend Recommendation (SGEN)
Comtex SmarTrend(R) - Tue Oct 21, 11:21AM CDT
SmarTrend identified a Downtrend for Seattle Genetics (NASDAQ:SGEN) on September 22nd, 2014 at $39.86. In approximately 4 weeks, Seattle Genetics has returned 11.52% as of today's recent price of $35.27.
SGEN: 36.05 (+1.20)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Oct 17, 7:16PM CDT
Cramer is focusing on earnings next week from many companies including Apple, Yahoo!, 3M and Procter & Gamble.
MMM: 156.55 (+0.50), F: 14.17 (-0.02), SDRL: 21.77 (+0.06), PEP: 96.80 (-0.01), MTD: 277.69 (+14.07), DPS: 69.95 (+0.01), YHOO: 48.55 (+0.62), LNCO: 21.91 (+0.01), IBM: 162.07 (+0.61), S: 4.72 (+0.03), CMG: 649.03 (+1.91), DE: 88.66 (+0.89), CAT: 101.76 (+0.85), PPG: 206.90 (+0.81), AAPL: 109.01 (+0.31), UVE: 18.10 (-0.67), REGN: 377.84 (+0.90), KO: 42.32 (+0.03), GPRO: 79.06 (+0.30), HD: 97.65 (+0.36), NYCB: 15.91 (+0.07), SGI: 9.61 (+0.19), VFC: 69.79 (+0.88), TAP: 77.18 (+0.13), DIS: 90.00 (-2.00), BAC: 17.36 (unch), BMY: 58.32 (-0.14), BA: 124.45 (-0.13), MTW: 21.13 (+0.16), CELG: 106.45 (-0.69), NFLX: 384.16 (+0.86), AA: 16.33 (-0.04), GS: 190.71 (-0.29), SGEN: 36.05 (+1.20), GILD: 106.45 (-0.49), PG: 89.13 (+0.23), SXL: 50.87 (+2.47), BABA: 114.56 (+2.99)
Stock Weakness in Seattle Genetics, Gilead Sciences Belies Fundamental Strengths
at The Street - Wed Oct 15, 8:35AM CDT
Some perspective on recent positive news, which nonetheless, caused Seattle Genetics and Gilead shares to fall.
SGEN: 36.05 (+1.20), GILD: 106.45 (-0.49)
Shares of SGEN Down 19.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Oct 14, 11:06AM CDT
SmarTrend identified a Downtrend for Seattle Genetics (NASDAQ:SGEN) on September 22nd, 2014 at $39.86. In approximately 3 weeks, Seattle Genetics has returned 19.00% as of today's recent price of $32.29.
SGEN: 36.05 (+1.20)
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2014 Financial Results on October 30, 2014
Business Wire - Tue Oct 14, 8:01AM CDT
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its third quarter 2014 financial results on Thursday, October 30, 2014 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
SGEN: 36.05 (+1.20)
Recent News posted below.
SGEN Seattle Genetics Recent Headline News
3 Biotech Stocks to Watch in November
Motley Fool Staff - Motley Fool - Sat Nov 08, 10:03AM CST
Investing in biotech companies can be tricky, especially for investors who don't have a scientific background or who don't completely understand the process of bringing new drugs to the marketplace. Fortunately, the Fool is here to help. We asked...
AVNR: 13.02 (-0.19), SGEN: 36.05 (+1.20), GILD: 106.45 (-0.49), ABBV: 61.50 (-1.21), GSK: 44.91 (+0.16)
Seattle Genetics to Present Clinical Data from Broad ADCETRIS(R) (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014
Business Wire - Fri Nov 07, 8:00AM CST
--Fifteen ADCETRIS Data Presentations, Including Seven Oral Presentations, Support Goal to Establish ADCETRIS as the Foundation of Therapy for CD30-Positive Malignancies
SGEN: 36.05 (+1.20)
Seattle Genetics (SGEN) Shows Signs Of Being Water-Logged And Getting Wetter
at The Street - Thu Nov 06, 9:18AM CST
Trade-Ideas LLC identified Seattle Genetics (SGEN) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
SGEN: 36.05 (+1.20)
Research and Markets: Mycosis Fungoides Therapeutics Pipeline Review, H2 2014 Report Featuring Sanofi, Seattle Genetics, Inc, Echo Therapeutics, Inc. & Actelion Ltd
Business Wire - Thu Nov 06, 4:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mlg9h9/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2014" report to their offering.
ECTE: 0.67 (unch), SGEN: 36.05 (+1.20)
Mycosis Fungoides Therapeutics Pipeline Review, H2 2014 Report Featuring Sanofi, Seattle Genetics, Inc, Echo Therapeutics, Inc. & Actelion Ltd
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/n96mgn/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mycosis Fungoides, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mycosis Fungoides and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - Seattle Genetics, Inc. - Echo Therapeutics, Inc. - Actelion Ltd Drug Profiles - brentuximab vedotin - mechlorethamine hydrochloride - alemtuzumab - methotrexate - NSC-678515 - CIGB-128 For more information visit http://www.researchandmarkets.com/research/n9..._fungoides
ECTE: 0.67 (unch), SGEN: 36.05 (+1.20)
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014 - 38 Companies & 67 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/rdllgl/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Idera Pharmaceuticals, Inc. - Mesoblast Limited - Jazz Pharmaceuticals plc - Alexion Pharmaceuticals, Inc. - Soligenix, Inc. - NeoStem, Inc. - Pharmacyclics, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Kamada Ltd. - R-Tech Ueno, Ltd. - Omni Bio Pharmaceutical Inc. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/rd...ersus_host
BIIB: 320.75 (-2.72), PCYC: 133.49 (-3.63), PSTI: 2.66 (-0.08), NBS: 4.85 (unch), ALDR: 16.57 (-0.25), IDRA: 2.43 (-0.06), SGEN: 36.05 (+1.20), JAZZ: 170.80 (-1.57), ALXN: 193.81 (+0.67), KMDA: 4.15 (+0.15), ATHX: 1.53 (-0.04), NVS: 91.76 (-0.27)
Seattle Genetics to Present at Credit Suisse Healthcare Conference
Business Wire - Tue Nov 04, 8:00AM CST
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 11, 2014, at 8:30 a.m. Mountain Time. The presentation will be webcast live and available for replay from Seattle Genetics' website at www.seattlegenetics.com in the Investors and News section.
SGEN: 36.05 (+1.20)
Seattle Genetics Gains on Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 11:50AM CST
Seattle Genetics, Inc. (SGEN) reported a loss of 13 cents per share in the third quarter, narrower than the Zacks Consensus Estimate of a loss of 25 cents.
MDVN: 112.77 (+7.82), BIIB: 320.75 (-2.72), SGEN: 36.05 (+1.20), GILD: 106.45 (-0.49)
Cramer Sees HP Entering Sector as Trouble for 3-D Printing Stocks
at The Street - Mon Nov 03, 10:57AM CST
Even though HP won't start shipping its 3-D printing machines in bulk until 2016, it could be a problem for other 3-D printing companies.
BMRN: 83.91 (-0.12), ISIS: 44.59 (-0.66), SGEN: 36.05 (+1.20), GILD: 106.45 (-0.49), SSYS: 103.07 (-3.26), HP: 86.70 (+0.98), REGN: 377.84 (+0.90), CELG: 106.45 (-0.69)
Seattle Genetics, Inc. Posts Record Adcetris Sales
Brian Orelli, The Motley Fool - Motley Fool - Thu Oct 30, 7:27PM CDT
Seattle Genetics is up in after-hours trading after posting record sales for its blood cancer drug Adcetris, and raising guidance for the year. The biotech sold $48 million worth of Adcetris in the U.S. and Canada, a 32% year-over-year increase. ...
SGEN: 36.05 (+1.20), GSK: 44.91 (+0.16)
Seattle Genetics beats Street 3Q forecasts
Automated Insights - Thu Oct 30, 6:13PM CDT
BOTHELL, Wash. (AP) _ Seattle Genetics Inc. (SGEN) on Thursday reported a third-quarter loss of $15.6 million.
SGEN: 36.05 (+1.20)
Seattle Genetics Reports Third Quarter 2014 Financial Results
Business Wire - Thu Oct 30, 3:06PM CDT
---ADCETRIS 2014 Net Sales Guidance Increased to a Range of $172 Million to $177 Million-
SGEN: 36.05 (+1.20)
Aegerion, Seattle Genetics CEOs Accused in Suit of Cocaine Use
at The Street - Mon Oct 27, 9:24AM CDT
Both CEOs deny allegations in an ugly divorce case that they snorted cocaine with a Jefferies & Co. health care investment banker.
SGEN: 36.05 (+1.20), AMGN: 160.25 (-0.10), AEGR: 21.58 (-0.40), REGN: 377.84 (+0.90)
Global B-Cell Non-Hodgkin Lymphoma Therapeutics Pipeline Review H2 2014 - 43 Drug Profiles from 28 Leading Pharma Companies
M2 - Thu Oct 23, 10:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72dlvw/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - Sanofi - Seattle Genetics, Inc. - Genentech, Inc. - MedImmune, LLC - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Biocon Limited - Ono Pharmaceutical Co., Ltd. - Sandoz Inc. - Celgene Corporation - Incyte Corporation - Merck KGaA - Immunomedics, Inc. - Portola Pharmaceuticals, Inc. - Pharmacyclics, Inc. - Takara Bio Inc. - Simcere Pharmaceutical Group - Spectrum Pharmaceuticals, Inc. - Cornerstone Pharmaceuticals, Inc. - LFB S.A. - Eagle Pharmaceuticals Inc. - Areta International s.r.l. - Molecular Templates Inc. - Aprogen, Inc. - BioMedics Japan Inc. For more information visit http://www.researchandmarkets.com/research/72dlvw/bcell
IMMU: 3.61 (+0.05), PTLA: 27.39 (-0.33), PCYC: 133.49 (-3.63), INCY: 69.32 (+0.92), AMGN: 160.25 (-0.10), SPPI: 7.33 (-0.15), BMY: 58.32 (-0.14), EGRX: 12.48 (-0.17), SGEN: 36.05 (+1.20), MRK: 59.34 (+0.08), CELGZ: 3.24 (-0.04)
Seattle Genetics Has Returned 11.5% Since SmarTrend Recommendation (SGEN)
Comtex SmarTrend(R) - Tue Oct 21, 11:21AM CDT
SmarTrend identified a Downtrend for Seattle Genetics (NASDAQ:SGEN) on September 22nd, 2014 at $39.86. In approximately 4 weeks, Seattle Genetics has returned 11.52% as of today's recent price of $35.27.
SGEN: 36.05 (+1.20)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Oct 17, 7:16PM CDT
Cramer is focusing on earnings next week from many companies including Apple, Yahoo!, 3M and Procter & Gamble.
MMM: 156.55 (+0.50), F: 14.17 (-0.02), SDRL: 21.77 (+0.06), PEP: 96.80 (-0.01), MTD: 277.69 (+14.07), DPS: 69.95 (+0.01), YHOO: 48.55 (+0.62), LNCO: 21.91 (+0.01), IBM: 162.07 (+0.61), S: 4.72 (+0.03), CMG: 649.03 (+1.91), DE: 88.66 (+0.89), CAT: 101.76 (+0.85), PPG: 206.90 (+0.81), AAPL: 109.01 (+0.31), UVE: 18.10 (-0.67), REGN: 377.84 (+0.90), KO: 42.32 (+0.03), GPRO: 79.06 (+0.30), HD: 97.65 (+0.36), NYCB: 15.91 (+0.07), SGI: 9.61 (+0.19), VFC: 69.79 (+0.88), TAP: 77.18 (+0.13), DIS: 90.00 (-2.00), BAC: 17.36 (unch), BMY: 58.32 (-0.14), BA: 124.45 (-0.13), MTW: 21.13 (+0.16), CELG: 106.45 (-0.69), NFLX: 384.16 (+0.86), AA: 16.33 (-0.04), GS: 190.71 (-0.29), SGEN: 36.05 (+1.20), GILD: 106.45 (-0.49), PG: 89.13 (+0.23), SXL: 50.87 (+2.47), BABA: 114.56 (+2.99)
Stock Weakness in Seattle Genetics, Gilead Sciences Belies Fundamental Strengths
at The Street - Wed Oct 15, 8:35AM CDT
Some perspective on recent positive news, which nonetheless, caused Seattle Genetics and Gilead shares to fall.
SGEN: 36.05 (+1.20), GILD: 106.45 (-0.49)
Shares of SGEN Down 19.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Oct 14, 11:06AM CDT
SmarTrend identified a Downtrend for Seattle Genetics (NASDAQ:SGEN) on September 22nd, 2014 at $39.86. In approximately 3 weeks, Seattle Genetics has returned 19.00% as of today's recent price of $32.29.
SGEN: 36.05 (+1.20)
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2014 Financial Results on October 30, 2014
Business Wire - Tue Oct 14, 8:01AM CDT
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its third quarter 2014 financial results on Thursday, October 30, 2014 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
SGEN: 36.05 (+1.20)
